

The Drug Diversion Triad The Drug Diversion Triad

Maureen Burger, Chief Nursing Officer, Visante.

2021-10-12

- Identify one change in DEA rules due to COVID-19
- Describe at least two workflow changes during COVID-19 that created unintended opportunities for diversion
- Relate human responses to COVID-19 and impact on rate of drug diversion in healthcare
- Evaluate three drug diversion risk mitigation strategies

This document is only available to subscribers

<u>Purchase</u>

Copyright © 2024 by Society of Corporate Compliance and Ethics (SCCE) & Health Care Compliance Association (HCCA). No claim to original US Government works. All rights reserved. Usage is governed under this website's <u>Terms of Use</u>.